Seasonal Affective Disorder

2018-04-24 15:11:31

Market Overview
According to a new report published by Reports Monitor titled, “Seasonal Affective Disorder Market by Type, Diagnosis, Treatment and End-User: Global Opportunity Analysis and Industry Forecast, 2017–2025,” the seasonal affective disorder market was valued at XX million in 2016, and is projected to reach at XX million by 2025, growing at a CAGR of XX% from 2017 to 2025. 

Seasonal affective disorder is form of depression in which people experience depressive episodes during specific time of the year. SAD is not considered as a separate disorder but rather is a type of depression that has recurring seasonal patterns. Common pattern starts in fall or winter that diminishes in the spring whereas summer depression is less common type of SAD. Sad is thought to be related with changes in the amount of daylight a person receives. Symptoms associated with SAD are hopelessness, change in appetite, weight gain or loss, less energetic and sleeping problems. 

Request a Sample Copy @

According National Health Services near about 1 in every 15 people in the US during a period of September to April suffers with seasonal affective disorder. Rising predominance and increasing awareness drives the growth of the market. In addition inactive lifestyle and lack of exercise further expected to boost the market growth. Availability and acceptance of new treatment alternative fuel the growth of the market. However, less awareness among people associated with disease and its treatment might restrict the growth of the market. Growing number of cases found in North America supports the growth of the seasonal affective disorder market growth in this region. According to Health Research Foundation every year 10 million American’s suffer from SAD and 10-20% may experience mild episodes. 

The global seasonal affective disorder market is segmented on the basis of type, diagnosis, treatment, end-user and region. Based on type, the market is divided into fall and winter SAD, spring and summer SAD, and others. In terms of diagnosis, the market is segregated into physical exam, lab tests, psychological evaluation, and others. Lab tests are sub-categorized into complete blood count (CBC), thyroid blood tests, and others. On the basis of treatments, the market is split into light therapy (phototherapy), medications, psychotherapy, counselling, and others. Medications include antidepressants, and others. Antidepressant is further sub-segmented into reuptake inhibitors (SSRIs), and others. On the basis of end user, it is segmented into hospitals & clinics, academic institutes, medical research centers, and others.

Competitive Landscape
Major Key players profiled in the report include AbbVie Inc., Bayer AG, Bristol-Myers Squibb Company, Allergan, F. Hoffmann-La Roche Ltd., Pfizer Inc. and Henry Schein, Inc. 

About Garner Insights:

We at Garner provide a comprehensive analysis by providing in-depth reports of the various market verticals. Our Mission is to provide a detailed analysis of the vast markets worldwide backed by rich data. Decision makers can now rely on our well-defined data gathering methods to get the correct and accurate market forecasting along with detailed analysis.

Contact Us:

Kevin Thomas


+1 513 549 5911 (US)

+44 203 318 2846 (UK)

Email: [email protected] 

Related Press Releases